Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.75 |
| ▸ | ABL1 | P00519 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.51 |
| ▸ | SGK1 | O00141 | 3/20 | 0.51 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13342181 | 0.91 | MAP4K1 (0.62) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL12763583 | 0.90 | MAP4K1 (0.73) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL1516740 | 0.90 | MAP4K1 (0.73) | MAP4K1ABL1CAMKK2MAP3K11KIT | |
| SCHEMBL13342256 | 0.89 | MAP4K1 (0.72) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL12763586 | 0.88 | MAP4K1 (0.70) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL14042964 | 0.87 | MAP4K1 (0.58) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL12763056 | 0.86 | MAP4K1 (0.81) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL12763016 | 0.86 | MAP4K1 (0.84) | MAP4K1ABL1CYP3A4CAMKK2KIT | |
| SCHEMBL13342184 | 0.86 | MAP4K1 (0.56) | MAP4K1ABL1CYP3A4CAMKK2SGK1 | |
| SCHEMBL1516599 | 0.86 | MAP4K1 (0.72) | MAP4K1ABL1CYP3A4CAMKK2SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | MAP4K1 6/4885ABL1 235/4885CYP3A4 3697/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | MAP4K1 14/4885ABL1 96/4885CYP3A4 4563/4885 |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | MAP4K2, PDXK, MAP4K1 | MAP4K1 3/4885ABL1 348/4885CYP3A4 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.